{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bates J"],"funding":["Health Technology Assessment Programme","National Institute for Health Research (NIHR)"],"pagination":["e060815"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9024265"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(4)"],"pubmed_abstract":["<h4>Background</h4>Hidradenitis suppurativa (HS) is a chronic, painful, inflammatory skin disease with estimates of prevalence in the European population of 1%-2%. Despite being a relatively common condition, the evidence base for management of HS is limited. European and North American management guidelines rely on consensus for many aspects of treatment and within the UK variations in management of HS have been identified. The HS James Lind Alliance Priority Setting Partnership (PSP) published a top 10 list of future HS research priorities including both medical and surgical interventions. The aims of the THESEUS study are to inform the design of future HS randomised controlled trials (RCTs) and to understand how HS treatments are currently used. THESEUS incorporates several HS PSP resea"],"journal":["BMJ open"],"pubmed_title":["Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): protocol for a prospective cohort study."],"pmcid":["PMC9024265"],"funding_grant_id":["17/98/01","PDF-2017-10-075"],"pubmed_authors":["Howells LM","Rodrigues J","Thomas KS","Hood K","Leighton P","Stanton H","Gibbons A","Thomas-Jones E","Cannings-John R","Ingram JR","Howes R","Harris C","Bates J","Collier F"],"additional_accession":[]},"is_claimable":false,"name":"Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): protocol for a prospective cohort study.","description":"<h4>Background</h4>Hidradenitis suppurativa (HS) is a chronic, painful, inflammatory skin disease with estimates of prevalence in the European population of 1%-2%. Despite being a relatively common condition, the evidence base for management of HS is limited. European and North American management guidelines rely on consensus for many aspects of treatment and within the UK variations in management of HS have been identified. The HS James Lind Alliance Priority Setting Partnership (PSP) published a top 10 list of future HS research priorities including both medical and surgical interventions. The aims of the THESEUS study are to inform the design of future HS randomised controlled trials (RCTs) and to understand how HS treatments are currently used. THESEUS incorporates several HS PSP resea","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-29T10:59:07.667Z","creation":"2025-04-06T19:47:56.653Z"},"accession":"S-EPMC9024265","cross_references":{"pubmed":["35450918"],"doi":["10.1136/bmjopen-2022-060815"]}}